University Hospital Virgen de la Victoria
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perez, Jose
NCT03596385 / 2017-002485-40: TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Completed
4
8507
Europe
Beta blocker, atenolol, bisoprolol, carvedilol, metoprolol, nevibolol.
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Myocardial Infarction
01/25
01/25
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
170
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Loxo Oncology, Inc., Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
05/27
08/32
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
02/26
02/26
GLOBAL-AKI, NCT05387811: International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

Completed
N/A
1456
Europe, US, RoW
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Azienda Ospedaliera di Padova
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
09/23
11/23
NCT04780542: Internet-delivered Cognitive Behavioral Treatment of Depression and Anxiety in Latin American College Students

Active, not recruiting
N/A
1500
RoW
Yo Puedo Sentirme Bien- Clinician-Guided version, Yo Puedo Sentirme Bien- Self-Guided version
Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente, National Institute of Mental Health (NIMH), Harvard Medical School (HMS and HSDM)
Major Depressive Disorder, Generalized Anxiety Disorder
05/25
06/25
IONA-MM, NCT04458831: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Active, not recruiting
N/A
586
Europe, Japan, US, RoW
isatuximab SAR650984, Sarclisa, Pomalidomide, Pomalyst, Dexamethasone, Carfilzomib
Sanofi
Plasma Cell Myeloma
02/26
02/26
Burgos, Guillermo Gonzalo Ojeda
DOBLEI, NCT06423898: Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.

Not yet recruiting
4
284
Europe
Experimental regimen, Control regimen
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, Spanish Clinical Research Network - SCReN
Endocarditis, Infective
07/27
12/28
NEW_SAFE, NCT03941951: Study to Optimize the Use of New Antibiotics

Recruiting
N/A
900
Europe
Non-impositive Program for Optimizing the Use of Antimicrobials
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Bacterial Infections, Fungal Infection
12/20
12/22

Download Options